Aflibercept

Not Applicable

02/01/2024 Anti-vascular endothelial growth factors for treating diabetic macular oedema and age-related macular degeneration

The Ministry of Health’s Drug Advisory Committee has recommended:

• Faricimab 6 mg/0.05 mL vial for treating adults with visual impairment due to:

  • diabetic macular oedema; and

  • neovascular (wet) age-related macular degeneration.

Funding status

[R] Faricimab 6 mg/0.05 mL vial is recommended for inclusion on the MOH Medication Assistance Fund (MAF) for the abovementioned indications from 1 March 2024.

[NR] MAF assistance does not apply to any formulations or strengths of aflibercept for treating diabetic macular oedema or neovascular age-related macular degeneration.

12/07/2022 Aflibercept, bevacizumab and ramucirumab for treating metastatic colorectal cancer

[NR] The Ministry of Health’s Drug Advisory Committee has not recommended aflibercept, bevacizumab reference biologic (Avastin) or ramucirumab for subsidy for treating metastatic colorectal cancer.

[NR] Bevacizumab (Avastin) has not been recommended in view of unfavourable cost effectiveness compared with bevacizumab biosimilar (Mvasi) at the price proposed by the manufacturer.

[NR] Aflibercept has not been recommended due to low clinical need and unfavourable cost effectiveness compared with Mvasi.

[NR] Ramucirumab has not been recommended following a request from the manufacturer to not consider it for subsidy.

Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration